Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA-CMS Parallel Reviews: Too Close for Comfort?

This article was originally published in RPM Report

Executive Summary

Parallel reviews by FDA and CMS are back on the table. While the proposed voluntary program seems harmless enough, drug and biotech companies may have good reason to be wary of greater collaboration between FDA and CMS officials.
Advertisement

Related Content

Building the Right Foundation: An Interview with Mark McClellan
EPO Market Stabilizes, But For How Long?
The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness
EPO Market Stabilizes, But For How Long?
The Other Agency: CMS Shocks Wall Street-and Amgen Takes a Hit
CMS: The Clinical Trials Agency?
Parallel Advice: A False Step in March to Globalized New Drug Reviews?
Parallel Advice: A False Step in March to Globalized New Drug Reviews?
Fashionably Early: When to Make Your Case to CMS
Fashionably Early: When to Make Your Case to CMS

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080394

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel